Ann Arbor’s NeuMoDx Molecular Partners with Italy’s Sentinel Diagnostics to Create Molecular Tests

Ann Arbor’s NeuMoDx Molecular, a molecular diagnostic company focused on developing testing solutions for hospital and commercial reference laboratory customers, has partnered with Italy’s Sentinel Diagnostics, which develops and produces diagnostic kits for clinical chemistry, immunochemistry, and molecular biology, to develop diagnostic assays.
494
NeuMoDx machine
NeuMoDx Molecular and Sentinel Diagnostics are working together to develop diagnostic assays. Pictured is a NeuMoDx diagnostic machine. // Photo courtesy of NeuMoDx

Ann Arbor’s NeuMoDx Molecular, a molecular diagnostic company focused on developing testing solutions for hospital and commercial reference laboratory customers, has partnered with Italy’s Sentinel Diagnostics, which develops and produces diagnostic kits for clinical chemistry, immunochemistry, and molecular biology, to develop diagnostic assays.

The collaboration will result in a broad portfolio of molecular diagnostic assays, providing a variety of clinical applications. The new test pipeline for the NeuMoDx systems will include assays to detect and monitor post-transplant infections, parasitic and hospital acquired infections, respiratory infections, and for pharmacogenetics applications.

NeuMoDx offers solutions that integrate the entire molecular diagnostic process from extraction to detection, with the first test available in about one hour. Its analyzers provide operators with the ability to load up to 288 patient samples in a continuous, random-access workflow resulting in on-demand, high throughput sample processing with a true operator walkaway window of up to eight hours.

“Sentinel Diagnostics is a leader in developing innovative tests to meet the diagnostic testing needs of the clinical diagnostics laboratory, and we are excited to partner with them as we continue to expand the test menu on our fully automated continuous random-access NeuMoDx Molecular systems,” says Jeff Williams, chairman and CEO of NeuMoDx.

Sentinel has more than 35 years of experience in the development and production of in vitro diagnostic devices. Its real-time PCR assays will be adapted to the NeuMoDx 96 and 288 Molecular Systems (testing systems) and will incorporate Sentinel’s STAT-NAT technology, which stabilizes the activity of PCR Mix, allowing for room-temperature transport and storage, performance improvement and long shelf life.

“Today, laboratories worldwide need to increase efficiency and throughput while continuing to provide high quality results” says Ugo De Luca, CEO of Sentinel. “Vast experience in (in vitro diagnostic) development/manufacturing enabled Sentinel to develop STAT-NAT patented technology and produce lyophilized ready-to-use molecular tests, with high sensitivity and specificity.

“In addition, with room temperature transport and storage, STAT-NAT assays are eco-friendly, saving energy and reducing CO2 emissions. The partnership with NeuMoDx Molecular Systems is a win-win for both companies and benefits patients and diagnostic labs worldwide.”

Facebook Comments